Navigation Links
Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome
Date:7/21/2014

ent, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases.  Specifically, Regulus is developing RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, and RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection.  Regulus' commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec focused on microRNA biomarkers.  In addition, the Company has established Regulus microMarkers™, a research and development division focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. 

For more information, please visit http://www.regulusrx.com

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with financial estimates (including Regulus' projected cash at the end of 2014), the projected sufficiency of Regulus' capital position for future periods, the expected ability of Regulus to undertake certain activities and accomplish certain goals (including with respect to development and other activities related to
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
2. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
3. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
4. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
5. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
6. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
7. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
8. Regulus Appoints Mark G. Foletta to its Board of Directors
9. Regulus to Present at Two Upcoming Investor Conferences
10. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
11. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 Even the ... of the Food and Drug Administration,s landmark approval of ... 11 members of Congress calling on the Agency to ... a first-ever medical treatment for women,s most common sexual ... FDA-approved medical treatment options for sexual dysfunction – while ...
(Date:3/26/2015)... and STAEFA, Switzerland , March ... the Venture platform, wirelessly transmits sound from the unaidable ear ... ear. This allows people with single-sided deafness to hear speech ... new fitting process for Phonak CROS II is as easy ... instantly experience the benefits of the CROS solution during the ...
(Date:3/26/2015)... 26, 2015  An Ohio entrepreneur is introducing a product ... As CEO for a start-up company known as SEED ... new business that will empower individuals to manage, review, and ... insecure methods. ... – will enable people to protect their own health records ...
Breaking Medicine Technology:Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 2Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 3Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 4Phonak CROS II: The smart solution for single-sided deafness 2Ohio Entrepreneur Develops Technology that Allows Patients Control Over Their Healthcare Records 2Ohio Entrepreneur Develops Technology that Allows Patients Control Over Their Healthcare Records 3Ohio Entrepreneur Develops Technology that Allows Patients Control Over Their Healthcare Records 4
... SAN FRANCISCO, Oct. 26, 2011 Nektar Therapeutics (Nasdaq: ... third quarter ended September 30, 2011 on Wednesday, November 2, ... president and chief executive officer, will host a conference call ... (ET)/2:00 p.m. Pacific Time (PT). The press ...
... Galleon Pharmaceuticals, a leader in the pharmaceutical treatment of ... has elected Thomas J. Dietz, Ph.D., as the company,s ... Holdings, LLC, a diversified financial-holdings and services company.   ... then CEO and a director of Pacific Growth Equities, ...
Cached Medicine Technology:Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets 2Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2
(Date:3/26/2015)... San Diego (PRWEB) March 26, 2015 ... to advance health and wellness for the poor and ... the application period for its annual $1 million award, ... is excited to announce the 2015 round of our ... "We've seen and supported some incredibly creative and ambitious ...
(Date:3/26/2015)... Calif. (PRWEB) March 26, 2015 UC ... innovative research into the origins of schizophrenia: A Silvio ... one of only 15 such centers in the United ... $10 million grant from the National Institutes of Mental ... investigate the novel hypothesis that an origin of schizophrenia ...
(Date:3/26/2015)... Tampa, FL (PRWEB) March 26, 2015 Florida ... the Taking Action For Your Health campaign and live Dr. ... mall on Saturday, March 21st. More than a thousand people ... message of healthy living. , The world renowned cardiothoracic ... Action News anchor Linda Hurtado and a panel of experts ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Xarelto ... forward nationwide, with the issuance of new court ... and Louisiana. According to an Order dated March ... established for Xarelto injury claims in the U.S. ... allow plaintiffs to file cases directly in the ...
(Date:3/26/2015)... March 26, 2015 Building off ... continuing medical education, the Cardiometabolic Risk Summit ... at Tulane University are proud to announce ... The interdisciplinary program , which ultimately ... is designed for physicians, nurse practitioners, physician assistants, ...
Breaking Medicine News(10 mins):Health News:Applications Open for $1M Innovation Initiative Award from Alliance Healthcare Foundation 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 3Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 4Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 2Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 3Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3
... conducted this study which was self funded. The sweetness ... of the sweetener. // The researchers questioned about 30 ... sweeteners and sweet substances. This was done to detect ... with each substance. Sugar was rated highest. Participants found ...
... with fish oil supplements in teenagers.,Durham County Council’s senior ... 25 teenagers who had been rated with moderate to ... omega-3 fish and omega-6 evening primrose oil over a ... students aged 12 to 15 also had a high ...
... Prime Minister, Shaukat Aziz has been urged by the Poultry ... the poultry industry//. The industry is under crisis over the ... flu scare and the earthquake that hit the country on ... President of the Lahore Chamber of Commerce and Industry (LCCI) ...
... developed at Leeds that will benefit at large in ... the next generation// of miniaturized computers. ,By suspending ... and Dr Yulong Ding have created ‘nanofluids’ which can ... In a central heating system, nanofluids could increase efficiency ...
... Court, would ensure that patients or their relatives would be ... demand. Until now, patients and family members have been facing ... doctor or hospital as they tend to treat it as ... it is their property and therefore refuse to give the ...
... jointly by University of California, Berkeley, and Chilean researchers says ... in drinking water are more likely to succumb to lung ... in their adult life. ,It was found that ... than normal if the child's mother also drank the arsenic-contaminated ...
Cached Medicine News:Health News:Sweet, Sweeter and Sweetest 2Health News:Poultry Industry Of Pakistan Stresses On Need Of Relief Package 2Health News:Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life 2
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
... Liquichek Hematology-16 Control is ... on most hematology analyzers ... 16 parameters and 3-part ... This trilevel control can ...
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
Medicine Products: